000288564 001__ 288564
000288564 005__ 20250415112710.0
000288564 0247_ $$2doi$$a10.1038/s41541-024-00832-0
000288564 0247_ $$2pmid$$apmid:38402256
000288564 037__ $$aDKFZ-2024-00410
000288564 041__ $$aEnglish
000288564 082__ $$a610
000288564 1001_ $$0P:(DE-He78)35b8b312f24f786ff12489e8b1cf05ee$$aZhang, Yueru$$b0$$eFirst author$$udkfz
000288564 245__ $$aInter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.
000288564 260__ $$a[London]$$bNature Publishing Group$$c2024
000288564 3367_ $$2DRIVER$$aarticle
000288564 3367_ $$2DataCite$$aOutput Types/Journal article
000288564 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712310095_9904
000288564 3367_ $$2BibTeX$$aARTICLE
000288564 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288564 3367_ $$00$$2EndNote$$aJournal Article
000288564 500__ $$a#EA:F035#LA:F035# /NEU/ #EA:D335#LA:D335#
000288564 520__ $$aThe human papillomavirus minor capsid protein L2 is being extensively explored in pre-clinical studies as an attractive vaccine antigen capable of inducing broad-spectrum prophylactic antibody responses. Recently, we have developed two HPV vaccine antigens - PANHPVAX and CUT-PANHPVAX- both based on heptameric nanoparticle antigens displaying polytopes of the L2 major cross-neutralizing epitopes of eight mucosal and twelve cutaneous HPV types, respectively. Prompted by the variable neutralizing antibody responses against some of the HPV types targeted by the antigens observed in previous studies, here we investigated the influence on immunogenicity of six distinct glycine-proline spacers inserted upstream to a specific L2 epitope. We show that spacer variants differentially influence antigen immunogenicity in a mouse model, with the antigen constructs M8merV6 and C12merV6 displaying a superior ability in the induction of neutralizing antibodies as determined by pseudovirus-based neutralization assays (PBNAs). L2-peptide enzyme-linked immunosorbent assay (ELISA) assessments determined the total anti-L2 antibody level for each antigen variant, showing for the majority of sera a correlation with their repective neutralizing antibody level. Surface Plasmon Resonance revealed that L2 epitope-specific, neutralizing monoclonal antibodies (mAbs) display distinct avidities to different antigen spacer variants. Furthermore, mAb affinity toward individual spacer variants was well correlated with their neutralizing antibody induction capacity, indicating that the mAb affinity assay predicts L2-based antigen immunogenicity. These observations provide insights on the development and optimization of L2-based HPV vaccines.
000288564 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000288564 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288564 7001_ $$0P:(DE-HGF)0$$aMariz, Filipe Colaco$$b1
000288564 7001_ $$aSehr, Peter$$b2
000288564 7001_ $$aSpagnoli, Gloria$$b3
000288564 7001_ $$0P:(DE-HGF)0$$aKoenig, Karl Moritz$$b4
000288564 7001_ $$0P:(DE-He78)32e22d1c8416af3f2a612da9121f2c05$$aÇelikyürekli, Simay$$b5$$udkfz
000288564 7001_ $$aKreuziger, Tim$$b6
000288564 7001_ $$0P:(DE-He78)2d5634b584ebede249368464b907e28c$$aZhao, Xueer$$b7$$udkfz
000288564 7001_ $$aBolchi, Angelo$$b8
000288564 7001_ $$aOttonello, Simone$$b9
000288564 7001_ $$0P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aMüller, Martin$$b10$$eLast author$$udkfz
000288564 773__ $$0PERI:(DE-600)2882262-6$$a10.1038/s41541-024-00832-0$$gVol. 9, no. 1, p. 44$$n1$$p44$$tnpj vaccines$$v9$$x2059-0105$$y2024
000288564 8564_ $$uhttps://inrepo02.dkfz.de/record/288564/files/s41541-024-00832-0.pdf
000288564 8564_ $$uhttps://inrepo02.dkfz.de/record/288564/files/s41541-024-00832-0.pdf?subformat=pdfa$$xpdfa
000288564 8767_ $$8SN-2024-00420-b$$92024-05-28$$d2025-04-14$$eAPC$$jZahlung erfolgt
000288564 909CO $$ooai:inrepo02.dkfz.de:288564$$pVDB$$pOpenAPC$$popenCost
000288564 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)35b8b312f24f786ff12489e8b1cf05ee$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000288564 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000288564 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000288564 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)32e22d1c8416af3f2a612da9121f2c05$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000288564 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d5634b584ebede249368464b907e28c$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000288564 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000288564 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000288564 9141_ $$y2024
000288564 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ VACCINES : 2022$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:19Z
000288564 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:19Z
000288564 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:19Z
000288564 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:11:19Z
000288564 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ VACCINES : 2022$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000288564 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000288564 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000288564 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000288564 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000288564 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000288564 9202_ $$0I:(DE-He78)F035-20160331$$kF035$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000288564 9201_ $$0I:(DE-He78)F035-20160331$$kF035$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000288564 9201_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x1
000288564 9200_ $$0I:(DE-He78)F035-20160331$$kF035$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000288564 980__ $$ajournal
000288564 980__ $$aVDB
000288564 980__ $$aI:(DE-He78)F035-20160331
000288564 980__ $$aI:(DE-He78)D335-20160331
000288564 980__ $$aUNRESTRICTED
000288564 980__ $$aAPC